FULFILLING OUR COMMITMENT TO PATIENTS
Biohaven has earned its reputation as a leader in scientific innovation. Our portfolio includes treatments for a range of diseases with unmet medical needs including focal epilepsy, obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA) and more. We are proud of our pioneering science and a growing pipeline built by our own discoveries and collaborations with others. We continue to apply scientific breakthroughs to make a difference in the lives of people living with debilitating diseases around the world.
RESEARCH PIPELINE
Our broad and growing R&D pipeline includes an array of novel therapies for people suffering from neurological and neuropsychiatric diseases, rare disorders and other strategic therapeutic adjacencies. Our diverse portfolio includes numerous product candidates across all stages of development.
ION CHANNEL Kv7 ACTIVATOR
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILED
MORE INFO
ION CHANNEL TRPM3
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILED
MORE INFO
INFLAMMATORY: TYK2/JAK1 INHIBITOR
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILED
MORE INFO
GLUTAMATE PLATFORM
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILED
MORE INFO
MYOSTATIN PLATFORM
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILED
MORE INFO
BISPECIFIC TARGETED CELL THERAPY
INDICATION
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILED
MORE INFO
DISCOVERY RESEARCH
PLATFORM / PROGRAM
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
FILED
MORE INFO